AstraZeneca PLC on Monday said Enhertu reduced the risk of disease progression in a form of breast cancer. The Cambridge, England-based pharmaceutical company said Enhertu plus pertuzumab reduced the ...

DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient ...

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

AstraZeneca on Sunday said its monoclonal antibody Imfinzi in combination with standard of care chemotherapy demonstrated significant and meaningful improvement in event-free survival in early stage ...

After rapid expansion, signs of a slowdown raise questions about future opportunities in the sector When it emerged that ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

AstraZeneca PLC (NASDAQ:AZN), a pharmaceutical and biotech firm based in Cambridge, UK, reported positive results from its Phase 3b Batura trial. The study found that Airsupra, its dual-action asthma ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a bispecific antibody newly licensed by Pfizer.

A new pre-surgery treatment strategy for inherited breast cancer has achieved an astonishing 100% survival rate, thanks to a ...

Cambridge: AstraZeneca has announced that Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) ...

Anglo-Swedish pharma major AstraZeneca reports that it will have a historic presence at this year’s American Society of ...